TFAM and chronic obstructive pulmonary disease: The animal experiments conducted in the present study also revealed that the activity of the AMPK/Sirt1‐PGC‐1α‐TFAM pathway was reduced in mice with COPD and that rhCC16 administration activated this pathway and mitigated COPD‐like symptoms.